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Abstract
The incidence of peripheral, cerebro- and cardiovascular disease (CVD) in patients with type 2 dia-
betes mellitus is approximately twice as high as in the non-diabetic population. Conventional cardio-
vascular risk factors such as plasma lipids, lipoproteins and hypertension only partially explain this
excessive risk of developing atherosclerosis and CVD. Meta-analysis of studies performed in non-
diabetic populations indicates that the risk of CVD increases continuously with glucose levels
above 4.2 mmol/l. The glucose hypothesis suggests that treatment which normalizes glucose levels
prevents or delays the long-term complications of diabetes mellitus. However, the outcome of the
UK Prospective Diabetes Study demonstrates that glucose control does not completely prevent CVD.
In healthy subjects, serum IGF-I levels peak in early adulthood, after which they gradually decrease
with increasing age. Several observations suggest that there is a premature and progressive age-
related decline in serum IGF-I bioactivity in type 2 diabetics, which eventually results in a (relative)
IGF-I deficiency. In type 2 diabetics, close relationships have been demonstrated between glycaemic
control and serum IGF-I levels, with worse control being associated with lower IGF-I levels. Several
studies (in non-diabetics) suggest that lowered circulating IGF-I levels account for a poor outcome of
CVD. We previously observed in a population-based study that a genetically determined lowered IGF-I
expression increases the risk of myocardial infarction with type 2 diabetes.
This genetic approach overcomes the problem that cross-sectional studies cannot distinguish
whether changes in IGF-I levels are a cause or a consequence of a disease. IGF-I is an important
metabolic regulatory hormone. In addition, IGF-I suppresses myocardial apoptosis and improves myo-
cardial function in various models of experimental cardiomyopathy. Compared with other growth fac-
tors, the ‘survival’ effect of IGF-I on myocardium seems rather unique.
Therefore, we hypothesize that the premature and progressive decline in serum IGF-I bioactivity in
ageing patients with type 2 diabetics is an important pathophysiological abnormality. It contributes
not only to elevated glucose and lipid levels, but also to the progression and the poor outcome of CVD.
If this hypothesis is proven to be right, treatment with IGF-I as an adjunct to insulin offers great
potential and might not only improve metabolic control but also reduce the incidence and prevalence
of CVD in type 2 diabetes patients. However, there is as yet no experimental evidence that long-term
(replacement) treatment with IGF-I prevents, delays or reduces CVD in type 2 diabetes patients. Clini-
cal trials are necessary to prove that long-term IGF-I treatment, preferably in the form of a better-
tolerated IGF-I/IGF-binding protein-3 complex, improves the overall cardiovascular risk in type 2
diabetes.
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Introduction
The incidence of cardiovascular disease (CVD), particu-
larly coronary heart disease (CHD), cerebrovascular,
and peripheral vascular disease is approximately twice
as high in patients with type 2 diabetes as in age-
matched controls without diabetes (1–4). The risk of
these complications increases with the duration of
diabetes and with age (5–7). In subjects with type 2
diabetes, CVD is associated with a higher mortality
rate than in non-diabetic subjects (8, 9). Conventional
cardiovascular risk factors such as plasma lipids, lipo-
proteins and hypertension only partially explain this
excessive risk of developing atherosclerosis and CVD
in individuals with type 2 diabetes (6, 10). In addition,
despite a marked decline in the rate of CVD over the
past 35 years in the overall population, this beneficial
trend has not been observed for subjects with type 2
diabetes (11).
Another important manifestation of CVD in diabetic
patients is heart failure (HF). The special role of
diabetes in the development of congestive HF was
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firmly established in the Framingham Study (12). In
this study the risk of HF was increased 2.4-fold in dia-
betic men and 5-fold in diabetic women. Diabetes pre-
dicted HF independently of coexisting hypertension or
CHD. HF is sometimes due to a diabetic cardiomyopathy,
which is now recognized as a distinct entity (13). Dia-
betic cardiomypathy appears to be independent of
macrovascular/microvascular disease and contributes
significantly to CVD morbidity and mortality, especially
in those diabetics with coexistent hypertension (14).
Abundant literature evidence supports the concept of
myocardial dysfunction separate from epicardial coron-
ary disease in diabetic individuals (15, 16).
Glucose control, insulin treatment and
CVD in the UK Prospective Diabetes
Study (UKPDS)
The glucose hypothesis suggests that treatment that
normalizes glucose levels prevents or delays the long-
term complications of diabetes mellitus. Based on the
UKPDS it has been suggested that the benefits of strict
glycaemic control in type 2 diabetes are less than
those of tight blood pressure control (17). Although
in the primary analysis of the UKPDS no significant
reduction in the risk of CVD was observed after strict
glycaemic control, mean glycosylated haemoglobin
(HbA1c) levels achieved in the UKPDS did not reach
the non-diabetic (normal) range. In addition, epidemio-
logical subanalysis of the UKPDS data suggested that a
reduction of HbA1c levels by 1% was associated with a
14% reduction in myocardial infarctions and a 12%
reduction in strokes (18). These epidemiological data
show that glucose-directed therapy which is sufficient
to lower glucose levels to normal produces a ‘normal’
population risk for macrovascular problems. Neverthe-
less, the overall outcome of the UKPDS makes clear that
CVD cannot be completely prevented by the common
methods of blood glucose control which are clinically
available today (19).
Impaired glucose tolerance (IGT),
hyperinsulinaemia, insulin resistance
and CVD
It has long been known that even IGT is associated with
an increased risk for CVD, while progression from IGT
to type 2 diabetes is not necessary in order to cause
CVD (20). The Whitehall study, the Honolulu Heart
Study and the Rancho Bernardo Study have prospec-
tively followed large cohorts of non-diabetic subjects
for cardiovascular outcomes (21 –23). In these three
studies a continuous increase in the risk for CHD was
observed with increasing serum glucose levels. In
accord, a meta-analysis of various cohort studies in
non-diabetic populations demonstrated that the
increased risk of CVD increased continuously with glu-
cose levels above 4.2 mmol/l (24). All these studies
suggest that long-term hyperglycaemia is an important
risk factor for CVD, without evidence of a threshold
effect and independently of other common risk factors
for CHD. Furthermore, subjects with insulin resistance
who are not diabetic, e.g. patients with the metabolic
syndrome X characterized by hypertriglyceridaemia,
hypertension and abdominal obesity, are also at
increased risk of CVD (25).
Insulin-like growth factor-I (IGF-I),
insulin and the IGF-binding proteins
(IGFBPs)
In man there are two important glucose-regulating
hormonal systems, insulin and IGF-I (26). In the
human body, IGF-I is after insulin the second most
powerful naturally occurring peptide with glucose-
lowering effects (27). The effects of IGF-I and insulin
are complementary. Insulin stimulates the constitutive
secretion of IGF-I from the liver (28). IGF-I in turn, sup-
presses insulin secretion even in euglycaemic con-
ditions (29). IGF-I increases insulin sensitivity and
peripheral glucose uptake, decreases hepatic glucose
production, and improves the lipid profile (30, 31).
IGF-I is probably the most potent anti-catabolic and
anabolic hormone in the body (32).
At least six IGFBPs and several proteases modulate
the bioavailability of IGF-I to the tissues (33). In the
blood, where IGF concentrations are 1000 times
higher than those of insulin, IGFBP-3 (the major form
of the IGFBPs in the circulation) binds in healthy sub-
jects at least 80% of IGFs as 140 kDa complexes,
which do not cross the capillary endothelium and
therefore prevent the insulin-like action of IGFs (34).
Under normal circumstances less than 1% of IGF-I
circulates in the free form (35). Nevertheless, these
circulating IGF reserves may be mobilized in response
to metabolic and other needs via limited proteolysis
of IGFBP-3 by serine proteases (36).
Ageing, glucose metabolism and insulin
resistance
Ageing is characterized by progressive alterations in
glucose metabolism, including resistance to insulin-
mediated glucose disposal, impaired glucose-induced
insulin release and altered hepatic glucose output
(37). The progression from normal glucose tolerance
via IGT to diabetes is a consequence of a further decline
in insulin secretion by the b-cell and/or an increase in
insulin resistance with ageing (38). In addition,
changes in body composition, as well as physical fit-
ness, may contribute to a further reduction of insulin
resistance with ageing.
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Is there a progressive IGF-I deficiency in
type 2 diabetes with ageing?
In patients with type 2 diabetes, serum IGF-I levels are
dependent on the degree of metabolic control, with
near normal IGF-I levels in well-controlled diabetics,
whereas they tend to decrease in poorly controlled dia-
betics (39 –41). It has also been suggested that lowered
serum IGF-I concentrations predict worsening of insu-
lin-mediated glucose uptake in older people (42). In
healthy subjects, serum total IGF-I levels peak in early
adulthood and then start to decline to 50% of adoles-
cent values in the fifth and sixth decades of life (43).
In type 2 diabetes this progressive age-dependent
decline of total IGF-I levels is even greater than that
observed in healthy controls. Tan & Baxter (44)
reported that circulating total IGF-I levels are lowered
in type 2 diabetic patients even after age was taken
into consideration.
Although the mechanism for the progressive reduction
of circulating IGF-I levels with ageing in patients with type
2 diabetes has remained obscure until now, it has been
suggested that this decrease is at least in part a result of
decreased IGF-I production through lowered growth hor-
mone (GH) concentrations and/or an uncoupling of the
GH induction of IGF-I generation by insulin resistance
(45). Another explanation might be central inhibition of
the GH/IGF-I axis. Increased demands for IGF-I with
ageing, resulting in accelerated metabolic clearance rate
of IGF-I by displacement of IGF-I from circulating
IGFBP-3 and transport of IGF-I to peripheral tissues may
also contribute to the progressive decrease of circulating
IGF-I concentrations. It has been speculated that
increased serum IGFBP-3 protease activity, as observed
in insulin-resistant states and type 2 diabetes, is an
endogenous compensatory mechanism to increase IGF-I
bioavailability at the tissue level in order to restore insulin
sensitivity, glycaemic control and other IGF-I-dependent
effects (46–48).
It has also been reported that subjects with insulin
resistance have initially decreased serum levels of
IGFBP-1 in comparison with those without insulin
resistance (49, 50). Although the biological signifi-
cance of reduced circulating IGFBP-1 levels in insulin-
resistant/hyperinsulinaemic states is unknown, it has
been suggested that low circulating IGFBP-1 concen-
trations might be another endogenous mechanism to
increase IGF-I bioavailability at the tissue level in an
attempt to stimulate glucose uptake in muscles and
other insulin-resistant tissues (51). However, ageing
and frank type 2 diabetes are both associated with a
reduction of insulin secretory rate as a consequence
of a progressive loss of b-cell function and this results
in an increase in IGFBP-1 levels (50, 52–55). Increased
IGFBP-1 levels are associated with a decreased IGF-I
bioactivity in diabetic serum (56) and in vivo data in
animals have shown that increased levels of IGFBP-1
can both inhibit IGF-I action and induce mild hypergly-
caemia (57). All these findings together suggest that in
type 2 diabetes during ageing there is a premature and
progressive decline in serum IGF-I bioactivity, resulting
in the development of a progressive (relative) IGF-I
deficiency, especially in those with a poor metabolic
control (see also Table 1).
Age, genetic susceptibility, IGF-I and type
2 diabetes
Age-related changes interact with the genetic back-
ground and may explain the increasing prevalence of
Table 1 Schematic time course of changes in circulating insulin, IGF-I/IGFBP levels and IGF-I bioactivity during the progression from
impaired glucose tolerance (IGT) to overt type 2 diabetes. Blood glucose levels rise at first, resulting in IGT, and finally in overt type 2
diabetes. Initially, insulin secretion increases to overcome insulin resistance, but reaches a plateau and then falls. IGFBP-1 levels are
thought to modulate the free fraction of IGF-I. IGFBP-1 levels are negatively regulated by insulin. It has been suggested that low
IGFBP-1 concentrations might increase the free IGF-I concentration in an attempt to stimulate glucose uptake in muscles and other
insulin-resistant tissues. The progression from IGT to frank type 2 diabetes is associated with a (relative) increase in IGFBP-1 levels
and as a consequence IGF-I bioactivity decreases. Increased IGFBP-3 proteolysis has been reported to occur in insulin-resistant states
and type 2 diabetes. It has been speculated that this increased protease activity in insulin-resistant states and diabetes is another
compensatory mechanism to attenuate the decrease in free IGF-I concentrations in order to restore insulin sensitivity and glycaemic
control. The physiological age-dependent decrease of IGF-I bioactivity is superimposed on the changes in circulating insulin and IGF-
I/IGFBP levels during the progression from IGT to overt type 2 diabetes (see also text).
Age
Normo-glycaemia IGT Overt type 2 diabetes
Insulin N " # or # #
IGFBP-1 N # N or "
Total IGF-I N N, # #
Free IGF-I N N, # # #
Intact IGFBP-3* N N, # # #
IGFBP3 protease activity N " " "
IGF-I bioactivity N N, # # #
N = normal; " = increased; # = decreased.
* Measured by Western ligand blotting.
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type 2 diabetes and diabetic complications during the
ageing process (37, 58).
Recently we observed in a population-based study of
elderly subjects higher circulating total IGF-I levels in
carriers of a genetic polymorphism in the promoter
region of the IGF-I gene than in non-carriers (59).
This study suggested that this IGF-I gene polymorphism
is functionally related to circulating IGF-I levels (59).
However, the main finding of this study was that both
the risk of type 2 diabetes and myocardial infarction
were significantly increased in non-carriers of this poly-
morphism when compared with carriers, suggesting
that a genetically determined exposure to relatively
low IGF-I levels plays a role in the pathogenesis of
type 2 diabetes and myocardial infarction (59).
IGF-I, diabetes and atherosclerosis
GH and IGF-I deficiency in non-diabetic humans are
associated with premature and increased atherosclero-
sis (60 –63). It was observed in hypophysectomized rats
that after vascular endothelial injury the proliferation
of vascular smooth muscle is markedly delayed,
suggesting an impaired adaptive response in the process
of healing of the injured arterial wall, when compared
with healthy control animals (64).
Atherosclerosis is also a major cause of morbidity
and mortality in patients with diabetes mellitus. Imbal-
ance between cell death and survival may substantially
affect the cellularity and integrity of the blood vessel
and contributes to the pathogenesis of atherosclerosis
(65). IGF-I is a potent survival factor preventing apop-
tosis of vascular smooth muscle cells (VSMCs) (66) as
well as stimulating the proliferation (67) and migration
of VSMCs (68). Thus, IGF-I may contribute in different
ways to the balance between apoptosis and survival in
atherosclerotic lesions (65).
IGF-I accumulation is found at the site of ischaemic
injury and VSMC proliferation is an important part of
the arterial response to injury (69). In an experimental
animal model it has been observed that vascular
smooth muscle proliferation after endothelial injury is
impaired by the diabetic state (69). In this experimental
model, IGF-I treatment enhances and normalizes vas-
cular smooth muscle proliferation (69).
Circulating IGF-I levels, like insulin, stimulate nitric
oxide (NO) in certain vascular beds (70 –74). Reduced
NO generation or accelerating NO inactivation may
Figure 1 Circulating total IGF-I levels in patients with significant
CAD (CAD+) and in those without (CAD 2 ) stratified by decades
of age. Each bar represents the mean^S.E.M. in each group.
Values for the number of patients of each subgroup are shown in
each box. Mean circulating total IGF-I levels were significantly
lower P , 0:01 in CAD+ patients 126^7 ng=ml; n  92 than in
CAD2 patients 162^15 ng=ml; n  30: When age was taken
into account circulating total IGF-I levels were significantly lower
in patients with CAD+ (two-way ANOVA, P , 0:05). (Reprinted
from (62) with permission from Excerpta Medica Inc.)
Figure 2 Circulating total IGF-I (A) and IGFBP-3 (B) levels in
healthy survivors and patients with poor clinical outcomes after an
acute myocardial infarction. Data are means^S.E.M. Mean total
IGF-I levels were significantly lower in patients who died n  2
or developed severe congestive HF n  4 during 3 months of
post-acute myocardial infarction follow-up * P , 0:001: In those
patients with poor outcomes, a borderline reduction of IGFBP-3
was observed on day 2 P  0:086: (Adapted from (83) with
permission from The Endocrine Society.)
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cause vascular damage and vascular dysfunction (75).
Vascular dysfunction is known to be associated with all
major risk factors for atherosclerosis, encompassing
hypertension and diabetes mellitus. Because NO is
essential for the integrity of the vessel wall, decreased
NO production by vascular endothelium, due to low
IGF-I levels, might be another pathogenic mechanism
responsible for the observed association between low
circulating IGF-I levels and atherosclerosis in diabetics
and non-diabetics (72). IGF-I can promote vasodilation
through the activation of potassium channels, with a
consequent reduction in the intracellular calcium con-
centrations (76 –79). In addition, IGF-I can stimulate
migration and tube formation by vascular endothelial
cells (80), has been shown to promote aortic angiogen-
esis (81), and inhibits adherence of human peripheral
blood monocytes to endothelial cells (82). All these
data together suggest a role for IGF-I deficiency per se
in increasing the atherosclerotic risk in diabetics and
non-diabetics.
IGF-I, diabetes and the heart
Low circulating IGF-I levels have been previously
associated with angiographically documented coronary
artery disease (CAD) in non-diabetics (62) (Fig. 1).
Immediately after acute myocardial infarction, lowered
circulating IGF-I levels were especially measured in
non-diabetic patients with poor outcomes (83) (Fig. 2).
Recently Friberg et al. (84) reported that non-diabetic
patients who died after an acute myocardial infarction
from CVD during 2 years of follow-up, had at admission
significantly lower IGF-I levels than survivors. In two
other studies, non-diabetic patients with myocardial
infarction had significantly lower IGF-I levels at admis-
sion than age- and sex-matched healthy controls (85,
86). In one of these latter studies older patients with
a cardiac condition were less able to maintain their
blood IGF-I levels during the recovery period than
younger patients (85) (Fig. 3). The authors suggested
that this observation may explain why older patients
take longer to recover and to heal after a myocardial
infarction than younger patients. These human studies
all suggest that lowered circulating IGF-I accounts for a
poor outcome of CVD.
Obviously, circulating IGF-I levels can decrease by
two mechanisms or their combination: (i) the pro-
duction of IGF-I is decreased and the efflux from the
circulation is unaltered, or (ii) the production is un-
altered and the efflux from the circulation is increased,
e.g. increased delivery of IGF-I at an injury of the vascu-
lar endothelium by an increased proteolysis of circu-
lating IGFBP-3 by specific IGFBP-3 proteases (87).
Probably both factors play a role in the reduction of cir-
culating IGF-I.
However, the most important issue in all these
human studies is to what extent low circulating IGF-I
Figure 3 Circulating total IGF-I levels following myocardial infarc-
tion compared with age- and sex-adjusted normal adults. Twenty-
one males and five females ranging in age from 19 to 71 years
were divided into two age groups: the first ranging from 19 to 48
years (nine males) (A) and the second ranging from 50 to 71
years (five post-menopausal females and 12 males) (B). Total
IGF-I levels in the older age group (B) showed a significant
decline from day 1 to day 4 P  0:001: Values of the younger
age group (A) remained stable from day 1 to day 4 compared with
the older group (B). Total IGF-I levels were significantly lower on
the first day compared with the age- and sex-adjusted total IGF-I
levels of normal adults (controls) aged ,50 years 197^44 vs
243^53 ng=ml; P  0:03 (A) and those aged .50 years 151^
43 vs 206^62 ng=ml; P  0:002 (B). In contrast to the younger
group, values of total IGF-I in the older group (.50 years)
remained significantly lower than those of controls on day 2 to
day 4. * P , 0:005: (Adapted from (85) with permission from
Harcourt Publishers Ltd.)
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levels are a cause or a consequence of the poor cardio-
vascular outcome. In our opinion the decrease in circu-
lating IGF-I levels is probably the cause and not the
consequence of the poor outcome of CVD. In the section
that follows we will give several arguments to support
this statement.
In a rabbit model, acute administration of IGF-I
just before and during early cardial ischaemia
improves glucose uptake and tolerance to ischaemia
in hypertrophied hearts (88). IGF-I has been shown
to have beneficial acute and long-term cardiovascular
effects in several other experimental studies. Poten-
tially beneficial effects of IGF-I observed in these
experimental studies are reduction in afterload
through vasodilation, positive inotropy, prevention of
apoptosis, increased calcium sensitivity of cardiac
myofilaments, improved recovery of cardiac function
after myocardial infarction and during reperfusion
after global ischaemia (88 –92).
In a previous study, as already discussed above, we
were able to confirm an increased risk for myocardial
infarction in diabetic and non-diabetic subjects with
genetically determined low IGF-I expression (59). A
genetic approach overcomes the problem that cross-
sectional studies cannot distinguish whether IGF-I
levels are a cause or a consequence of disease. The
increased risk for myocardial infarction in diabetics
with low IGF-I expression may thus for a large part
be explained by the interaction of low IGF-I availability
and coronary atherosclerosis. The study of Conti et al.
(86) supports this possibility. In this study low IGF-I
levels preceded the increase of creatine phosphokinase
in the very early phase of an acute myocardial infarc-
tion, which suggests also that some antecedent cause
and not the acute myocardial infarction was the
reason for the lowered IGF-I levels (86). In the same
study, patients with acute myocardial infarction
showed a trend toward higher insulin levels compared
with controls, which achieved statistical significance
at 1 year follow-up (86). The authors suggested that
these insulin levels were consistent with an insulin-
resistant state, in both the acute and chronic phases
of myocardial infarction.
Experimental evidence for IGF-I effects
on the heart
Effects on CHD
The importance of IGF-I as an anti-apoptotic factor is
also supported by the observation in different animal
models of myocardial ischaemia that IGF-I adminis-
tration decreased myocardial apoptosis and thereby
the size of myocardial infarction (89, 93). When the
coronary artery was ligated to create an experimental
myocardial infarction in mice, transgenic mice
overexpressing IGF-I in the myocardium showed
decreased cell death and less ventricular dilation and
wall stress (94). GH-deficient dwarf rats, with reduced
circulating IGF-I levels but normal myocardial IGF-I
mRNA levels, developed in an experimental model of
myocardial infarction more pathological left ventricular
remodelling and functional loss than did controls (95).
In another experimental model of myocardial infarction
a marked reduction in capillarization and a blunted
cardiac remodelling response following myocardial
infarction were observed in IGF-I-deficient mice, as
compared with controls (96).
Diabetic cardiomyopathy
In most forms of cardiomyopathy there is an initial
upregulation of myocardial IGF-I and IGF-I receptor
expression, which may be a transient, compensatory
remodelling response (97). In contrast, diabetic cardio-
myopathy is a unique myopathic state and differs from
other cardiomyopathies in that a decrease in both myo-
cardial IGF-I content and IGF-I receptors has been
observed (98). However, in IGF-I transgenic mice with
streptozotocin-induced diabetes, IGF-I overexpression
decreased the development of diabetic cardiomyopathy
by attenuating p53 function and angiotensin II pro-
duction (99). IGF-I improves myocardial function in
various models of experimental cardiomyopathy and
suppresses myocardial apoptosis (100–102). IGF-I
administration in animals with experimental cardiac
failure promoted a physiological form of myocardial
hypertrophy (i.e. there was no increase in extracellular
matrix or fibrosis) (101). The myocardial hypertrophy
was accompanied by an improved cardiac function
(decreased left ventricular end-diastolic volume and
increased stroke volume), suggesting a beneficial effect
of IGF-I. In another experimental animal model of HF,
IGF-I treatment decreased mean arterial pressure, left
ventricular end-diastolic pressure and systemic vascu-
lar resistance, and increased left cardiac index and
stroke volume index (103).
Recently it was shown that basal IGF-I levels are
reduced in dilated cardiomyopathy patients with
severe left ventricular dysfunction (104) and that
serum IGF-I levels are negatively correlated with the
severity of the cardiomyopathy (105). IGF-I improves
cardiac contractility, cardiac output, stroke volume
and ejection fraction by the human heart in the
short and long term (91). Adult humans with GH
deficiency and low IGF-I levels display slight cardiac
dysfunction, which can be reversed by GH replace-
ment therapy (106). IGF-I exerts calcium-dependent
positive inotropic effects in the failing human myo-
cardium (107). All these studies together suggest
that IGF-I deficiency may contribute to an adverse
outcome of CVD.
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Is decreased IGF-I a missing link which
raises both glucose levels and
cardiovascular risk in ageing patients
with type 2 diabetes?
Both the prevalence of type 2 diabetes mellitus and CVD
are increasing and associated with a very high mor-
tality rate, reduced quality of life and high costs of
treatment, despite intensive insulin treatment. New
strategies are urgently needed which slow or prevent
the development of type 2 diabetes and CVD better
than is currently achieved with the available treatment
options. Several studies, as discussed above, suggest
that the premature and progressive decline in serum
IGF-I bioactivity during ageing in patients with type 2
diabetes may result in insufficient protective and regen-
eration effects of IGF-I on the cardiovascular system. In
comparison with other growth factors, these ‘survival’
effects of IGF-I on the myocardium seem rather unique
(108). In addition, IGF-I enhances insulin sensitivity
and improves glycaemic control in type 2 diabetic sub-
jects significantly (109). In addition, IGF-I treatment
lowers both total and low-density lipoprotein choles-
terol and triglyceride levels in type 2 diabetics (110).
Lipoprotein(a) (Lp(a)), an important risk factor for
CAD, also improved after IGF-I treatment (89). The
risk of coronary thrombosis (as measured by plasmino-
gen activator inhibitor-1 and fibrinogen levels) also
improved after IGF-I treatment (111). Moreover, IGF-I
treatment decreases obesity and improves body compo-
sition of type 2 diabetics (109, 112). Taking all the
available information together, it becomes increasingly
clear that IGF-I is not only an important metabolic
regulatory hormone but also produces potent effects
on the cardiovascular system (see Table 2 for a sum-
mary of potential mechanisms). Therefore, we hypo-
thesize that in patients with type 2 diabetes the
accelerated decline in serum IGF-I bioactivity during
ageing is an important pathophysiological phenom-
enon, which not only results in raised glucose and
lipid levels but also contributes to the progression and
the poor outcome of CVD. However, the ‘IGF-I
deficiency hypothesis’ rests still to a great extent on
animal studies, which have been extensively referred
to in this manuscript, as well as on circumstantial evi-
dence. The decreased serum IGF-I level observed in sub-
jects with type 2 diabetes mellitus with poor glycaemic
control raises the possibility that exogenous recombi-
nant IGF-I acting as a form of ‘replacement’ therapy
might improve glucose tolerance and might inhibit
the development of CVD (43). Previous studies have
demonstrated that in type 2 diabetes circulating IGF-I
levels improve after better glycaemic control (43,
113 –115). IGF-I therapy as an adjunct to insulin
improved glycaemic control in type 2 diabetes and
reduced insulin resistance, a major component of the
pathophysiology of type 2 diabetes (31). To date, studies
of recombinant IGF-I administration to patients with
type 2 diabetes have used free IGF-I doses which were
associated with significant side-effects (arthralgias,
myalgias, dyspnoea, nerve entrapment, headache and
bilateral jaw tenderness) (31). These side-effects were
probably caused by the use of free IGF-I in excessive
doses. IGF-I administration inhibits GH secretion and
may therefore actually further decrease IGFBP-3 and
acid-labile subunit levels, which will result in a faster
clearance of IGF-I from the circulation and thus more
side-effects (116). Most pharmaceutical companies
have decided not to develop IGF-I treatment further
because of these side-effects (117). Recently, short-
term clinical trials using a complex of IGF-I/IGFBP-3
as an adjuvant to insulin therapy in patients with
type 2 diabetes caused a rapid fall in plasma glucose
concentrations and an improvement in insulin resist-
ance without any side-effects (118). There is as yet
no proof that (long-term replacement) therapy with
IGF-I as an adjunct to insulin will reduce, delay or
even prevent the risk of CVD in patients with type 2 dia-
betes. Further studies examining the efficacy and the
long-term safety of this IGF-I/IGFBP-3 combination
should be undertaken in patients with type 2 diabetes,
to investigate if this complex can modify the incidence
and prevalence of CVD in these patients.
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Table 2 Summary of the potential mechanisms by which IGF-I
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